CME 7 Session - EANM'14

Neuroimaging: Towards the Clinical Validation of Biomarkers for Alzheimer and Parkinson Diseases

Educational objectives:
  1. Understanding the potentialities and limitations of the most established biomarkers, their pitfalls, and the work that is on-going in the scientific community to validate them in large clinical series
  2. Underlying the role of different analytic approach to the Imaging Biomarkers, including Magnetic Resonance Imaging (MRI)
  3. Update on the role of 18F-FDG-PET in the context of the other biomarkers for Alzheimer’s disease (AD) and Parkinson’s Disease (PD)
  4. Update on the role of amyloid-PET in the context of the other biomarkers for AD and PD
There is a great effort nowadays to validate the most established biomarkers for AD and PD in large clinical populations. There has been a specific call of the EU Joint Programming on Neurodegenerative Disease (JPND) and the Project ‘BIOMARKAPD’ has been funded, involving an International taskforce of the main European Countries. Standardisation of measurement procedures and result interpretation is the hot topic for both cerebrospinal fluid and imaging biomarkers. The output of this project will hopefully be a milestone in the clinical use of biomarkers, today mostly limited to research centres. Metrics of MRI, 18F-FDG-PET and amyloid PET is under development and comparisons studies between different tools are on-going. This is of paramount importance since it has been shown that the choice of adequate metrics is at least as crucial as the choice of the biomarker itself. Also, diagnostic algorithms including neurodegeneration, amyloidosis and alpha-synuclein biomarkers should rationalise their employment and limit the costs.

Key Words:
Biomarkers, Alzheimer, Parkinson, PET, MRI, Amyloid, Synuclei
Teaser Video
A short description by the Swen Hesse, vice chair of the EANM Neuroimaging Committee

User action required
If you have the permission to view this publication, please log in.